The New Face of Personalized Medicine: Targeting Disease Diagnostics and Treatments with Big Data Analytics

Description

Thanks to stunning progress in technology development and biomedical research, we have more preventive, diagnostic, and treatment alternatives for human diseases than ever before. But we still don’t know what works in healthcare and for whom. The arrival of “Big data” – in genomics, proteomics, gene expression, systems biology, and healthcare informatics and so on – surely gives us the tools to make tremendous headway in developing personalized effective medicines. But where are the success stories to suggest that this will happen on a massive scale and in the near to mid future?

We invite you to join our moderator, Bio-IT World Editor-in-Chief Kevin Davies PhD, the author of The $1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine, and an exciting panel of three distinguished scientists who are shaping the new face of personalized medicine. We will also discuss how our industry can achieve targeted disease discovery that leads to treatments that work for all stakeholders.

Panel Participants:
- Eric Schadt PhD, Chief Scientific Officer Pacific Biosciences, recently appointed as Chairman and Professor of the Department of Genetics and Genomic Sciences and Director of the Institute for Genomics and Multiscale Biology at the Mount Sinai School of Medicine in New York,
- Felix Frueh PhD, President, Medco Research Institute
- Colin Hill, CEO and co-founder of GNS Healthcare, a healthcare analytics company that applies next-generation machine learning and simulation technologies to understand what works in healthcare, and for whom.

Among the questions we will be asking are:
• What does the imminent arrival of the $1,000 genome mean for diagnostics? For personalized medicine? For drug discovery and development? For health plans and providers?
• Will big data analytics be the key enabler of a new era of discoveries that will empower all stakeholders – pharma/biotech, government, health plans, providers and the empowered patient? Can these developments address the immense challenge of keeping our nation healthy while curbing healthcare costs?
• Can we accelerate our ability to directly use observational healthcare data (versus randomized controlled clinical trials) to transform how we think about ‘evidence’ and profoundly accelerate its creation, development, diffusion and use?
• And can we open the door to a rapid-learning healthcare system?

No related posts.